Key Points
- BDX EVP Michael Feld sold 165 shares for approximately $31,101 under a pre-arranged Rule 10b5-1 plan, reducing his position by 0.83% to 19,720 shares.
- Becton Dickinson exceeded quarterly expectations, reporting $3.23 in adjusted EPS and $4.98 billion in revenue, up 5.4% year over year. The company maintained fiscal 2026 EPS guidance of $12.62–$12.72.
- The stock recently traded near $188, while analysts’ consensus rating remained “Hold” with an average price target of $185.67; BDX also declared a quarterly dividend of $1.05 per share, yielding about 2.2% annually.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 165 shares of the firm's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Feld also recently made the following trade(s):
- On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $157.13, for a total value of $11,784.75.
- On Friday, June 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $152.80, for a total value of $11,460.00.
Becton, Dickinson and Company Trading Down 1.1%
NYSE:BDX opened at $188.11 on Friday. The stock has a market cap of $51.83 billion, a PE ratio of 56.66, a price-to-earnings-growth ratio of 13.41 and a beta of 0.19. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The stock's 50-day moving average is $165.23 and its two-hundred day moving average is $160.33.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the company posted $3.68 earnings per share. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is currently 126.51%.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. Jefferies Financial Group reiterated a "buy" rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Royal Bank Of Canada boosted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research note on Thursday, August 13th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research note on Monday, July 6th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Barclays increased their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a report on Monday, May 11th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $185.67.
Read Our Latest Analysis on BDX
Institutional Trading of Becton, Dickinson and Company
Several large investors have recently made changes to their positions in the stock. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier's stock worth $1,827,000 after buying an additional 1,354 shares during the period. United Bank boosted its holdings in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier's stock worth $887,000 after buying an additional 993 shares during the period. Marshall Wace LLP grew its stake in Becton, Dickinson and Company by 365.1% in the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier's stock valued at $5,491,000 after buying an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC raised its holdings in Becton, Dickinson and Company by 34.7% in the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier's stock worth $4,048,000 after acquiring an additional 6,058 shares during the period. Institutional investors own 86.97% of the company's stock.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
